Are FLT3 Inhibitors Likely to Improve FLT3 -Mutated Acute Myeloid Leukemia in the Foreseeable Future?
International Journal of Hematologic Oncology · 2016
DOI: 10.2217/ijh-2017-0001 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Hematologic Oncology, 2016. Verfasst von Sabine Kayser und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of Heidelberg.
Abstract (Originalsprache)
International Journal of Hematologic OncologyVol. 5, No. 4 EditorialAre FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?Sabine Kayser & Mark J LevisSabine Kayser Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) & Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany & Mark J Levis*Author for correspondence: E-mail Address: Levisma@jhmi.edu Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USAPublished Online:24 Feb 2017https://doi.org/10.2217/ijh-2017-0001AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: AMLFTL3 mutationsgeneticsleukemianovel therapyReferences1 The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368(22), 2059–2074 (2013).Crossref, Medline, Google Scholar2 Brandts CH, Sargin B, Rode M et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 65(21), 9643–9650 (2005).Crossref, Medline, CAS, Google Scholar3 Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am. Soc. Hematol. Educ. Program 2013, 220–226 (2013).Crossref, Medline, Google Scholar4 Kayser S, Levis MJ. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leuk. Lymphoma 55(2), 243–255 (2014).Crossref, Medline, CAS, Google Scholar5 Stone RM, Mandrekar S, Danford BL et al. The multi-kinase inhibitor midostaurin prolongs survival compared with placebo in combination with daunorubicin/cytarabine induction, high-dose cytarabine consolidation, and as maintenance therapy in newly diagnosed acute myeloid leukemia (AML) patients age 18–60 with FLT3 mutations: an international prospective randomized placebo-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Blood 126(22), Abstract 6 (2015).Medline, Google Scholar6 Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin. Ther. Targets 19(1), 37–54 (2015).Crossref, Medline, CAS, Google Scholar7 Wang ES, Stone RM, Tallman MS, Walter RB, Eckardt JR, Collins R. Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia. Blood 128(22), Abstract 1071 (2016).Google Scholar8 Perl AE, Altman JK, Cortes JE et al. Final results of the chrysalis trial: a first-in-human Phase 1/2 dose-escalation, dose-expansion study of gilteritinib (ASP2215) in patients with relapsed/refractory acute myeloid leukemia. Blood 128(22), Abstract 1069 (2016).Crossref, Google Scholar9 Galanis A, Ma H, Rajkhowa T et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 123(1), 94–100 (2014).Crossref, Medline, CAS, Google Scholar10 Lee LY, Hernandez D, Rajkhowa T et al. Pre-clinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood 129(2), 257–260 (2017).Crossref, Medline, CAS, Google Scholar11 Pratcorona M, Brunet S, Nomdedéu J et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 121(14), 2734–2738 (2013).Crossref, Medline, CAS, Google Scholar12 Schlenk RF, Kayser S, Bullinger L et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 124(23), 3441–3449 (2014).Crossref, Medline, CAS, Google Scholar13 Ivey A, Hills RK, Simpson MA et al. Assessment of minimal residual disease in standard-risk AML. N. Engl. J. Med. 374(5), 422–433 (2016).Crossref, Medline, CAS, Google Scholar14 Ravandi F, Alattar ML, Grunwald MR et al. Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23), 4655–4662 (2013).Crossref, Medline, CAS, Google Scholar15 Levis M, Miller J, Xie Z, McClain V, Carson A, Stenzel T. A novel next-generation sequencing based assay for FLT3/ITD mutations is sensitive and specific and can be used to detect minimal residual disease in AML patients. Haematologica Abstract P568 (2016).Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 5, No. 4 Follow us on social media for the latest updates Metrics Downloaded 53 times History Published online 24 February 2017 Published in print December 2016 Information© Future Medicine LtdKeywordsAML FTL3 mutationsgeneticsleukemianovel therapyFinancial & competing interests disclosureS Kayser gratefully acknowledges to be supported by the Olympia-Morata program of the Medical Faculty of the University of Heidelberg. MJ Levis is supported by a grant from the NCI (NCI Leukemia SPORE P50 CA100632). He receives research funding from Novartis and Astellas. He serves as a consultant for Novartis, Daiichi-Sankyo, Astellas and Arog. S Kayser has served as a consultant for Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.
- Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) & Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Förderung
- NCI NIH HHS
- University of Heidelberg
Zitieren
APA
Kayser, S., & Levis, M. J. (2016). Are FLT3 Inhibitors Likely to Improve FLT3 -Mutated Acute Myeloid Leukemia in the Foreseeable Future?. International Journal of Hematologic Oncology. https://doi.org/10.2217/ijh-2017-0001
Vancouver
Kayser S, Levis MJ. Are FLT3 Inhibitors Likely to Improve FLT3 -Mutated Acute Myeloid Leukemia in the Foreseeable Future?. International Journal of Hematologic Oncology. 2016. doi:10.2217/ijh-2017-0001
BibTeX
@article{Kayser2016,
author = {Kayser, Sabine and Levis, Mark J},
title = {Are FLT3 Inhibitors Likely to Improve FLT3 -Mutated Acute Myeloid Leukemia in the Foreseeable Future?},
journal = {International Journal of Hematologic Oncology},
year = {2016},
doi = {10.2217/ijh-2017-0001}
}
EUVIMED